ReachMD CME

First-line Chemotherapy Options in Metastatic PDAC

First-line Chemotherapy Options in Metastatic PDAC

Second-line Chemotherapy Options in Metastatic PDAC

Distinguishing Between Anti-PD-1 Agents in ESCC Combination Therapies

The Importance of PD-L1 Testing: Shaping the Future of Treatment in ESCC

Effective Monitoring and Management of Adverse Effects in Metastatic ESCC

Mutational Testing in mCRC: Methods and Data Driving Treatment Selection

From Guidelines to Practice: First-Line Treatment Choices in mCRC

Defining the Standard of Care and Optimal Sequencing in BRAF-Mutant mCRC: Second Line and Beyond

Proactive Adverse Effect Management in mCRC: Improving Tolerability to Optimize Patient Outcomes

Case Consult: Adverse Effect Monitoring, Management, and Mitigation During Targeted Therapy for BRAF-Mutant mCRC

Updates in Major Depressive Disorder with Insomnia

Understanding Endocrine Resistance in HR+/HER2- mBC

PI3K Pathway Inhibition in HR+/HER2- mBC: Mechanistic Insights

Comprehensive Biomarker Testing in mBC Informs Clinical Decision Making

Double Take: Pivotal Data Evaluating PI3K Inhibitor/Endocrine Therapy Regimens in mBC

Triple Threat: Key Data on Simultaneous Estrogen, CDK4/6, and PI3K Inhibition in mBC

Case in Point: Applying PI3K Combinations in Early Recurrent HR+/HER2- mBC

PI3K Pathway Inhibitors: Safety and Tolerability Profiles

The Future of PI3K Inhibition in HR+/HER2- Breast Cancer

Test Your Skills and Learn From Experts on IL-13 Inhibitors in Moderate to Severe Atopic Dermatitis

Guideline Recommendations in First-Line Treatment of HER2-Negative Upper GI Cancers

Pivotal Data in Anti-PD-1 Strategies for HER2-Negative Upper GI Cancers

Distinguishing First-Line Treatment Adverse Event Profiles in HER2-Negative Upper GI Cancers

Quick Case: Strategizing Treatment Selection in HER2-/PD-L1+ Gastric Cancer

From Resistance to Response: Evolving Strategies in MDD Management

Rethinking the Therapeutic Targeting of B7-H3 in ES-SCLC

Emerging Clinical Evidence for B7-H3–Directed ADCs in ES-SCLC From WCLC 2025

Translating Clinical Data Into Multidisciplinary Practice for ES-SCLC

Clinical Criteria and Imaging Strategies for B7-H3–Directed ADCs in ES-SCLC

Emerging Clinical Evidence for B7-H3–Directed ADCs in ES-SCLC From ESMO 2025

Clinical Implications of Emerging Data on B7-H3–directed ADCs in the Future of ES-SCLC

FSGS: When Solutions Fall Short

Current FSGS Treatment Landscape: More Questions Than Answers

FSGS: Interpretation of Proteinuria Reduction Thresholds

Emerging Therapies in Managing Adult and Pediatric Patients With FSGS: Latest Data

Monitoring FSGS: Traditional and Novel Biomarkers

DEARA Versus SOC in FSGS Management: Clinical Trial Insights

Treatment Considerations for Pediatric Patients With FSGS

Integrating the Patient Voice in FSGS Management

Future Directions in FSGS Care

Bronchiectasis Update: Diagnostic Innovations and Therapeutic Frontiers

Photobiomodulation: A Non-Invasive Treatment for Ocular Disease and Trauma

Clinical and Safety Outcomes from the LIGHTSITE III Trial

Anatomical Outcomes from the LIGHTSITE III Trial

Sustaining Visual Benefits of Photobiomodulation in Dry Age-Related Macular Degeneration

Best Practices for Optimized Photobiomodulation Treatment Effect: Candidate Selection

Patient-Centered Care and Integration of Photobiomodulation Therapy into Clinical Practice

Integration of Photobiomodulation Therapy into the Age-Related Macular Degeneration Treatment Landscape

Real-World Evidence of Photobiomodulation Efficacy in Ocular Indications

Collaborative Care for CRSwNP Expert and Patient Insights